Share via Email

* Email To: (Separate multiple addresses with a semicolon)
* Your Name:
* Email From: (Your IP Address is
* Email Subject: (personalize your message)

Email Content:

Novel Antibiotic Class Under Development


The Swiss Innovation Agency (Innosuisse) has granted funding jointly to a commercial entity Polyphor and the University of Zurich to develop a new class of antibiotics. The mode of action of the prototype Thanatin involves inhibition of a lipopolysaccharide transport pathway critical to maintain the outer membrane of Gram-negative bacteria. The new class referred to as Outer Membrane Protein Targeting Antibiotics (OMPTAs) is currently under evaluation to target multiple drug resistant strains of Pseudomonas aeruginosa.